Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical Presentation and Tumour Burden in Head and Neck Sarcomas: Implications for Early Diagnosis and Referral.

Cancers·2026

Same author

Echocardiography in cardio-oncology: optimising service delivery.

Echo research and practice·2026

Same author

Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial.

British journal of cancer·2026

Same author

Living with sarcoma in childhood: an indepth qualitative exploration of psychosocial factors.

Archives of disease in childhood·2026

Same author

Early Detection of Ototoxicity Using Serial Mobile Audiometry, Otoacoustic Emissions Testing, and Inner Ear Biomarker Measurement in Patients Receiving Platinum-Based Chemotherapy Treatment: It is Feasible to Implement in a National Health Service (NHS) Cancer Ambulatory Care Setting.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2026

Same author

Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium.

JCO precision oncology·2025

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Experimental therapies in Ewing's sarcoma.

Rachael Windsor¹, Sandra Strauss, Beatrice Seddon

¹The London Sarcoma Service, UCL Hospitals NHS Foundation Trust, First Floor Central, 250 Euston Road, NW1 2PG, London, UK. rachael.windsor@uclh.nhs.uk

Expert Opinion on Investigational Drugs

|February 25, 2009

Summary

New treatments for Ewing sarcoma/primitive neuroectodermal tumors (ES/PNET) show promise. Combining chemotherapy with targeted agents may improve outcomes for this aggressive cancer in young people.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Experiment Videos

Last Updated: Jun 25, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Area of Science:

Oncology
Cancer Research
Pediatric Oncology

Background:

Ewing sarcoma/primitive neuroectodermal tumors (ES/PNET) are aggressive musculoskeletal cancers.
These tumors disproportionately affect young individuals.
Current treatments result in frequent relapses and poor survival rates for metastatic disease.

Purpose of the Study:

To review current experimental treatment strategies for ES/PNET.
To explore future therapeutic prospects for ES/PNET.

Main Methods:

Literature review of established and experimental therapies.
Analysis of recent meeting presentations on cytotoxic and biological treatments for ES/PNET.

Main Results:

New combinations of conventional and novel cytotoxic agents show potential.
Molecular techniques are identifying high-risk patients and therapeutic targets.
Emerging biologically targeted agents demonstrate promising preliminary clinical efficacy.

Conclusions:

Combining novel targeted agents with current chemotherapy may enhance outcomes for ES/PNET.
Advancements in molecular techniques aid in personalized treatment approaches.
Further research into combined therapeutic strategies is crucial for improving ES/PNET patient survival.